GLP-1 drugs could have been developed decades earlier, but regulatory and system-level choke points made it costly and cumbersome to test them, demonstrating how process barriers inhibit innovation.
factualpending
Speaker
Ezra KleinEvidence Quote
“We could have had the GLP-1s decades ago. Um but there are a lot of reasons within the system that, you know, it would have been costly to try that out.”
Created: 8/11/2026, 6:51:20 AM
Your notes
Loading notes...